Literature DB >> 11091527

Breast Cancer: A Revolutionary Concept.

.   

Abstract

In this paper we trace the evolution of paradigms concerning the nature of breast cancer and their therapeutic consequences. There is no doubt that the conceptual revolution of about 20 years ago has led to modest gains in survival following the use of adjuvant systemic therapy and the quality of survival by demonstrating the safety of conservative surgical regimens. At the same time, there seems to be a plateau in progress. The results of adjuvant systemic therapy are not as good as anticipated and there are a number of other inconsistencies within the conventional model of biological predeterminism that remain to be explained. We offer up an alternative paradigm that suggests that not all metastases are due to cellular dissemination with late onset local and distant recurrence resulting from a transfection phenomenon, whereby subcellular particles shed by the primary cancer cell are taken up by wandering cells of the monocyte macrophage system and transported to distant sites where the local mesenchymal cells are transfected with the genetic information that activates components of the genome to instruct these plastic cells to express the phenotypic picture of a dedifferentiated breast duct epithelial cell. Such a conceptual revolution will open up the way for a new program of research and the development of therapies based on anti-viral rather than cytotoxic drugs.

Entities:  

Year:  1995        PMID: 11091527     DOI: 10.1007/BF02966891

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  53 in total

Review 1.  The generation of diversity and pattern in animal development.

Authors:  J B Gurdon
Journal:  Cell       Date:  1992-01-24       Impact factor: 41.582

2.  Biological predeterminism in human cancer.

Authors:  I MACDONALD
Journal:  Surg Gynecol Obstet       Date:  1951-04

3.  Poly (2'O-methylcytidylate).oligodeoxyguanylate, a template-primer specific for reverse transcriptase, is not utilized by HeLa cell gamma DNA polymerases.

Authors:  G F Gerard
Journal:  Biochem Biophys Res Commun       Date:  1975-04-07       Impact factor: 3.575

4.  Nucleotide sequence of human endogenous retrovirus genome related to the mouse mammary tumor virus genome.

Authors:  M Ono; T Yasunaga; T Miyata; H Ushikubo
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

5.  Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?

Authors:  M W Retsky; D E Swartzendruber; R H Wardwell; P D Bame
Journal:  Med Hypotheses       Date:  1990-10       Impact factor: 1.538

6.  Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2.

Authors:  C Dickson; R Smith; S Brookes; G Peters
Journal:  Cell       Date:  1984-06       Impact factor: 41.582

7.  Intracisternal A-type particle-mediated activations of cytokine genes in a murine myelomonocytic leukemia: generation of functional cytokine mRNAs by retroviral splicing events.

Authors:  K B Leslie; F Lee; J W Schrader
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

8.  Tumour dormancy: initiation, maintenance and termination in animals and humans.

Authors:  T H Stewart; A C Hollinshead; S Raman
Journal:  Can J Surg       Date:  1991-08       Impact factor: 2.089

9.  Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man.

Authors:  H H Kazazian; C Wong; H Youssoufian; A F Scott; D G Phillips; S E Antonarakis
Journal:  Nature       Date:  1988-03-10       Impact factor: 49.962

10.  Inflammatory cell infiltrates in human melanoma at different stages of tumor progression.

Authors:  E B Bröcker; G Zwadlo; B Holzmann; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

View more
  1 in total

1.  New hypothesis on the origin of metastases.

Authors:  Nicola Schischmanov
Journal:  Nagoya J Med Sci       Date:  2013-02       Impact factor: 1.131

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.